Peripheral ulcerative keratitis-like findings associated with filgrastim.
OBJECTIVE
To describe an ocular side effect occurring with filgrastim therapy.


METHODS
Retrospective case report.


RESULTS
One week after starting therapy with intravenous filgrastim, a 66-year-old woman developed bilateral keratitis, evidenced by epithelial defects and peripheral corneal infiltrates. When filgrastim was discontinued, symptoms improved within 3 days and resolved within 2 weeks.


CONCLUSIONS
Our patient's bilateral keratitis, which abated rapidly after discontinuation of filgrastim, may have been an adverse effect of this drug. Although the patient also took pamidronate, timing and resolution of symptoms make this a less likely culprit. Physicians should be aware of the possibility of filgrastim-associated keratitis, which can be managed by discontinuing the drug or treating with artificial tears.
Fraunfelder
Frederick W
FW
Casey Eye Institute, Oregon Health and Science University, Portland, OR 97239-4197 , USA. eyedrug@ohsu.edu
Harrison
Devin
D
D000368:Aged; D003320:Corneal Ulcer / Q000139:chemically induced* / Q000175:diagnosis; D005260:Female; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects*; D006801:Humans; D007262:Infusions, Intravenous; D011994:Recombinant Proteins; D012189:Retrospective Studies
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim